Douglas Lane & Associates LLC Trims Position in Organon & Co. (NYSE:OGN)

Douglas Lane & Associates LLC decreased its holdings in Organon & Co. (NYSE:OGN - Free Report) by 49.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 270,838 shares of the company's stock after selling 260,842 shares during the quarter. Douglas Lane & Associates LLC owned 0.11% of Organon & Co. worth $4,041,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in OGN. Prospera Private Wealth LLC bought a new stake in shares of Organon & Co. in the 3rd quarter worth $25,000. William B. Walkup & Associates Inc. bought a new stake in Organon & Co. in the 2nd quarter worth about $31,000. Versant Capital Management Inc increased its stake in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company's stock valued at $41,000 after buying an additional 1,324 shares during the last quarter. Abich Financial Wealth Management LLC increased its stake in Organon & Co. by 5,646.3% in the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company's stock valued at $45,000 after buying an additional 2,315 shares during the last quarter. Finally, Trust Co. of Vermont lifted its position in shares of Organon & Co. by 109.4% during the 3rd quarter. Trust Co. of Vermont now owns 2,626 shares of the company's stock worth $50,000 after buying an additional 1,372 shares in the last quarter. Institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Performance

Shares of OGN stock traded up $0.27 on Thursday, hitting $15.99. 3,894,028 shares of the stock were exchanged, compared to its average volume of 3,051,066. The firm's 50 day moving average is $15.41 and its two-hundred day moving average is $18.44. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The firm has a market capitalization of $4.12 billion, a PE ratio of 3.17, a P/E/G ratio of 0.81 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing analysts' consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the business earned $0.78 EPS. Organon & Co.'s revenue for the quarter was up 4.1% compared to the same quarter last year. Sell-side analysts expect that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were issued a dividend of $0.28 per share. The ex-dividend date of this dividend was Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.00%. Organon & Co.'s payout ratio is 22.22%.

Analysts Set New Price Targets

Separately, Evercore ISI raised Organon & Co. to a "strong-buy" rating in a research report on Wednesday, September 18th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.